Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study

Thomas Berg, Pietro Andreone, Stanislas Pol, Stuart Roberts, Zobair Younossi, Moises Diago, Eric J. Lawitz, Roberto Focaccia, Graham R. Foster, Andrzej Horban, Isabelle Lonjon-Domanec, Ralph Demasi, Gaston Picchio, Donghan Luo, Sandra De Meyer, Stefan Zeuzem

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Background & Aims: Predictors of response to treatment with peginterferon plus ribavirin are well established. In these post-hoc analyses of the REALIZE study, we sought to identify predictors of response for telaprevir-based triple therapy. Methods: Patients from the REALIZE study with baseline data for all predictors evaluated (including baseline disease characteristics and demographics, prior treatment response and baseline laboratory assessments) were included in the post-hoc analyses (n = 465). Univariate and multivariate analyses were used to evaluate factors predicting treatment outcomes. Results: Sustained viral response (SVR) rates were 86% in prior relapsers, 63% in prior partial responders and 32% in prior null-responders. In the final multivariate analysis, baseline factors predicting SVR were prior response to treatment [Odds ratio (OR) = 2.80; 95% confidence interval (CI), 2.13-3.69], low-density lipoprotein (LDL) (≥2.6 mmol/L) (OR = 2.11; 95% CI, 1.52-2.93), HCV genotype (OR = 0.58; 95% CI, 0.36-0.93), and maximum alanine amino transferase and aspartate amino transferase (OR = 0.62; 95% CI, 0.40-0.97). Conclusions: Prior response to peginterferon plus ribavirin treatment and LDL levels are the main independent predictive markers of response with telaprevir-based triple therapy.

Original languageEnglish (US)
Pages (from-to)448-454
Number of pages7
JournalLiver International
Volume35
Issue number2
DOIs
StatePublished - Feb 1 2015

Keywords

  • HCV
  • LDL
  • Predictors
  • REALIZE
  • Response
  • Telaprevir

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study'. Together they form a unique fingerprint.

Cite this